This is not a hit piece on a competitor, and I am not going to name one. It is a piece about how to read a clinic — because after the July FDA meeting, the single most useful thing a prospective patient can do is check whether the place they're considering has noticed what happened.
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for possible inclusion on the 503A bulk drug substances list. It recommended six. It declined one.
The one that was declined.
| Substance | Uses FDA evaluated | Committee outcome |
|---|---|---|
| BPC-157 | Ulcerative colitis | Recommended — 8–6–1 |
| KPV | Wound healing, inflammatory conditions | Recommended — 8–6–1 |
| TB-500 | Wound healing | Recommended — 8–6–1 |
| MOTS-c | Obesity, osteoporosis | Recommended — 7–5–2 |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Recommended — 8–5–1 |
| Epitalon | Insomnia | Recommended — 7–4–1 |
| Emideltide (DSIP) | Opioid withdrawal, chronic insomnia, narcolepsy | Not recommended — 6–7–1 |
DSIP — delta sleep-inducing peptide, formally emideltide — is the one. And the vote was close, 6 in favor to 7 against with one abstention, on a panel that had spent two days voting for substances its own FDA staff reviewers opposed. This was a committee inclined to say yes. It still said no to this one.
The reason is not mysterious. DSIP was isolated in the 1970s and has been studied intermittently ever since, and the human sleep literature is genuinely thin — small studies, inconsistent effects, no modern randomized trial establishing that it does the thing its name promises. For a committee already stretching to accommodate substances with limited data, DSIP fell below even that line.
Where it's still being sold.
In the weeks since the vote, I have been reading what clinics across North Georgia and East Tennessee are advertising. A pattern shows up often enough to be worth describing.
Named, pre-formulated peptide "blends," sold like menu items, are common in this market. One such blend advertised within thirty minutes of Dalton is marketed for sleep and lists three ingredients: DSIP, CJC-1295, and BPC-157.
Look at what that combination contains:
- DSIP — the one substance the FDA advisory committee declined, twelve days before I wrote this.
- CJC-1295 — not declined, because it was never on the docket at all. It has not been reviewed, is not a candidate for the 503A list, and is not lawful for human compounding in 2026. We have written before about why CJC-1295 is not on the Limitless menu and why we use tesamorelin instead.
- BPC-157 — recommended by the committee, but recommended for ulcerative colitis, which is not sleep. And a recommendation is not a rule; nothing has been added to any list.
So a single advertised product contains one rejected substance, one never-reviewed substance, and one substance recommended for an entirely different indication — sold as a sleep protocol. That is not a close call about evolving science. It is a page that nobody updated.
The claims are the bigger exposure.
The substances are one problem. The sentences around them are a larger one. In the same body of local marketing you will find, verbatim:
- "Because peptides are natural to our bodies, they're very well-tolerated and incredibly safe."
- Claims that a blend may "potentially extend lifespan" and "support telomeres from shortening."
- Copy still carrying a different clinic's name mid-paragraph, left over from a template.
Set aside the last one, which is merely embarrassing. The first two are the legal problem, and the July hearing made them worse rather than better.
Here is the mechanism. Unqualified safety and efficacy claims about non-FDA-approved compounded products have always been exposed under the advertising provisions at 21 CFR 202 and under the FTC Act, which requires competent and reliable scientific evidence behind a health claim. What changed in July is that the federal record now documents the absence of that evidence. FDA's own briefing materials, prepared for a public advisory committee, walk through exactly how thin the human data is for each of these substances. A clinic asserting that a peptide is "incredibly safe" or "clinically proven" is now making a claim contradicted by a published federal assessment.
This is not theoretical enforcement. FDA issued 30 warning letters in a single day in March 2026, and more than 80 to telehealth companies over the past year. Overwhelmingly, those letters were about what was said in the advertising — not about the clinical judgment behind the prescription. Legal commentators covering the July vote have been blunt that treating a committee recommendation as a green light carries enforcement risk until FDA formally lists a substance.
Four questions to ask any peptide clinic
- "Which peptides do you offer, by name, and is each one lawful to compound today?" A clinic that cannot answer this crisply — or that answers with a blend name instead of substances — is telling you something.
- "What did the July 2026 FDA committee actually decide, and what did it not decide?" The correct answer includes the phrase "a recommendation is not a rule."
- "Where does this come from, and can I see the per-lot certificate of analysis?" Licensed 503A pharmacy with per-lot CoA, or it's a gamble. "Research use only" material is not a sourcing lane for patient care.
- "Who wrote the page I read on your website, and when was it last updated?" Regulatory pages with no author and no date are the ones that go stale silently.
Expanded, with what a good answer sounds like versus a bad one — plus a fifth question about how the clinic makes money: Four questions to ask any peptide clinic →
What we do instead.
We don't sell blends. A pre-mixed, pre-named combination is a marketing object, not a clinical one — it fixes the ratio of several active substances before anyone has seen your labs, and it makes it impossible to change one variable at a time when something isn't working. Every peptide on a Limitless protocol is prescribed individually, for a stated reason, at a dose chosen for you.
We don't prescribe DSIP. We didn't before the vote and we won't after it. If you are not sleeping, that is a real clinical problem with a real workup — sleep apnea, cortisol rhythm, thyroid, alcohol, hormone status, medication timing — and a peptide with no modern randomized evidence is not where that investigation should start.
We don't prescribe CJC-1295, for the reason above. Tesamorelin, an FDA-approved GHRH analog with randomized CT-measured outcome data, is the GH-axis lead at this practice, and we've published exactly why.
And we hold ourselves to the same reading standard we're describing here. This site carried a page for three months that said a federal reclassification had "restored" access to tissue-repair peptides — which was backwards, since as FDA's own presenter noted at the July hearing, adding these substances would create legal access for the first time. We rewrote that page and said so in public rather than quietly editing it. The standard isn't never being wrong. It's showing your corrections.
The honest caveat
Nothing here means DSIP is dangerous, or that a clinic offering it is harming patients. The committee declined to recommend it for the 503A list because the evidence supporting its use was insufficient — that is a statement about proof, not about poison. A different panel on a different day might have voted 7–6 the other way.
What it means is narrower and more useful: the information required to know this was public, free, and twelve days old at the time of writing. A practice that markets a rejected substance in a named product, alongside one that was never reviewed, with the word "incredibly" doing load-bearing work in the safety claim, has told you how carefully it reads. That's worth knowing before you hand someone your labs.